Interstitial lung disease during trimethoprim/sulfamethoxazole administration

Syota Yuzurio, Naokatsu Horita, Yutaro Shiota, Arihiko Kanehiro, Mitsune Tanimoto

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)


We studied clinical and radiographic features of interstitial lung disease (ILD) during trimethoprim/ sulfamethoxazole (TMP/SMX) administration. Ten patients who had received prednisolone treatment for underlying diffuse pulmonary disease showed various ILDs after introduction of TMP/SMX. The radiographic features of the ILDs were not consistent with infectious disease or exacerbation of the underlying disease, and these diagnoses were excluded radiographically and on clinical grounds during the differential diagnosis of the ILDs. These ILDs emerged relatively early after introduction of TMP/SMX, which is consistent with the former case report of drug-induced ILD (DI-ILD) caused by TMP/SMX. Therefore DI-ILDs caused by TMP/SMX were suspected in these cases. In most of these cases, the ILDs were clinically mild and disappeared immediately although administration of TMP/ SMX was continued.

Original languageEnglish
Pages (from-to)181-187
Number of pages7
JournalActa medica Okayama
Issue number3
Publication statusPublished - Jul 2010


  • Clinical characteristic
  • Drug-induced interstitial lung disease
  • Radiographic findings
  • Trimethoprim/sulfamethoxazole

ASJC Scopus subject areas

  • General Biochemistry,Genetics and Molecular Biology


Dive into the research topics of 'Interstitial lung disease during trimethoprim/sulfamethoxazole administration'. Together they form a unique fingerprint.

Cite this